Category Archives: Global News Feed

Basel, 26 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS® (ocrelizumab) data on disease progression and healthcare costs in patients with early-stage RRMS and long-term safety from all clinical trials in patients with relapsing MS (RMS) and primary progressive MS (PPMS). Data from the largest database of pregnancy outcomes for an anti-CD20 therapy in MS suggest consistent outcomes with epidemiological data in pregnant women and was an oral presentation today at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

More:
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable...

Tumor outcomes and overall survival maintained in patients with HNC at one-year

Read the original:
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.

Here is the original post:
Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium

Utilizing decades of experience, Paschal will bring his strategic leadership and technical know-how to Growcentia as the company continues to expand Utilizing decades of experience, Paschal will bring his strategic leadership and technical know-how to Growcentia as the company continues to expand

Read the original:
Growcentia appoints Darrin Paschal as new chief commercial officer

LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 November 2022.

Read the original here:
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 9th, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Read more:
Cytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022